Literature DB >> 11154025

Evolution of antibiotic resistance in gram-positive pathogens.

A Marchese1, G C Schito, E A Debbia.   

Abstract

Staphylococcus aureus is a common cause of soft tissue infection, e.g. impetigo, cellulitis, or wound infection, and causes osteomyelitis, arthritis, bacteremia with metastatic infection, and scalded skin and toxic shock syndromes. Coagulase-negative staphylococci have become increasingly important causes of nosocomial bacteremia associated with invasive monitoring, intravascular catheters and prosthetic heart valves or joints. Most staphylococci produce b-lactamase and are resistant to penicillin. An increasing proportion of S. aureus have intrinsic resistance to methicillin (MRSA) and present major problems in hospitals for the control of cross infection. The glycopeptides, teicoplanin and vancomycin, are the antibiotics of first choice for treatment of these infections. After the first report describing a Japanese clinical isolate of vancomycin-resistant S. aureus (VRSA), several papers have documented the emergence of these microorganisms. Since the development and spreading of this phenomenon which is perceived as a fearsome threat to the already difficult therapy of nosocomial infections due to the prevalence of heterogeneous vancomycin resistance, we found the incidence of MRSA exceeds 35% in our hospital. Out of 179 methicillin-resistant S. aureus isolated during 1997-1998, two strains (1.1%) gave subclones with vancomycin MICs of 8 mg/L. PFGE showed identical restriction patterns for both isolates, suggesting transfer of a single clone between two different patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11154025     DOI: 10.1179/joc.2000.12.6.459

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  6 in total

1.  Characterization of IsaA and SceD, two putative lytic transglycosylases of Staphylococcus aureus.

Authors:  Melanie R Stapleton; Malcolm J Horsburgh; Emma J Hayhurst; Lynda Wright; Ing-Marie Jonsson; Andrej Tarkowski; John F Kokai-Kun; James J Mond; Simon J Foster
Journal:  J Bacteriol       Date:  2007-08-03       Impact factor: 3.490

Review 2.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus.

Authors:  Hildegard Etz; Duc Bui Minh; Tamás Henics; Agnieszka Dryla; Birgit Winkler; Christine Triska; Aoife P Boyd; Johannes Söllner; Walter Schmidt; Uwe von Ahsen; Michael Buschle; Steven R Gill; James Kolonay; Hanif Khalak; Claire M Fraser; Alexander von Gabain; Eszter Nagy; Andreas Meinke
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

4.  Novel topical microbicides through combinatorial strategies.

Authors:  Anubhav Arora; Samir Mitragotri
Journal:  Pharm Res       Date:  2010-03-20       Impact factor: 4.200

5.  Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment.

Authors:  Jon-David Schwalm; Philippe El-Helou; Christine H Lee
Journal:  Can J Infect Dis       Date:  2004-03

6.  Antimicrobial and DNA gyrase-inhibitory activities of novel clorobiocin derivatives produced by mutasynthesis.

Authors:  Ute Galm; Stefanie Heller; Stuart Shapiro; Malcolm Page; Shu-Ming Li; Lutz Heide
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.